Cancer stem cells in the human mammary gland and regulation of their differentiation by estrogen

Future Oncology

Volumn 7, Issue 8, 2011, Pages 995-1006

  Simões, Bruno M ^a   Vivanco, Maria Dm ^a  

^a CIC BIOGUNE   (Spain)

Author keywords

breast cancer; cancer stem cell; estrogen; stem cell; tamoxifen

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; DNA; ESTROGEN; ESTROGEN RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; TAMOXIFEN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

BREAST CELL; CANCER RECURRENCE; CANCER RELAPSE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL ISOLATION; CELL PROLIFERATION; DNA SEQUENCE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL CULTURE; MALIGNANT TRANSFORMATION; MAMMARY GLAND; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; ESTROGENS; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; NEOPLASTIC STEM CELLS; RECEPTORS, ESTROGEN; STEM CELLS;

EID: 80051729113     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.80     Document Type: Review

References (106)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100(7), 3983-3988 (2003). nn First identification of breast cancer stem cells. (Pubitemid 36418143)
2. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5), 555-567 (2007). nn Identification of the first functional marker shared by normal and breast cancer stem cells. (Pubitemid 350056407)
3. Pece S, Tosoni D, Confalonieri S et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140(1), 62-73 (2010). nn Highlights the correlation between cancer stem cell content and the heterogeneous phenotypical and molecular features of breast cancers.
4. Bocchinfuso WP, Korach KS. Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J. Mammary Gland Biol. Neoplasia 2(4), 323-334 (1997).
5. Burchell J, Durbin H, Taylor-Papadimitriou J. Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. J. Immunol. 131(1), 508-513 (1983). (Pubitemid 13069258)
6. Gudjonsson T, Villadsen R, Nielsen HL, Ronnov-Jessen L, Bissell MJ, Petersen OW. Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev. 16(6), 693-706 (2002). (Pubitemid 34274039)
7. Gusterson BA, Monaghan P, Mahendran R, Ellis J, O'Hare MJ. Identification of myoepithelial cells in human and rat breasts by anti-common acute lymphoblastic leukemia antigen antibody A12. J. Natl Cancer Inst. 77(2), 343-349 (1986). (Pubitemid 16039383)
8. Koukoulis GK, Virtanen I, Korhonen M, Laitinen L, Quaranta V, Gould VE. Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Correlations with their functions as receptors and cell adhesion molecules. Am. J. Pathol. 139(4), 787-799 (1991).
9. Tsai YC, Lu Y, Nichols PW, Zlotnikov G, Jones PA, Smith HS. Contiguous patches of normal human mammary epithelium derived from a single stem cell: Implications for breast carcinogenesis. Cancer Res. 56(2), 402-404 (1996). (Pubitemid 26026371)
10. Alvi AJ, Clayton H, Joshi C et al. Functional and molecular characterisation of mammary side population cells. Breast Cancer Res. 5(1), R1-R8 (2003).
11. Clayton H, Titley I, Vivanco M. Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp. Cell Res. 297(2), 444-460 (2004). (Pubitemid 38798406)
12. Dontu G, Abdallah WM, Foley JM et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17(10), 1253-1270 (2003). nn Validation of the sphere assay for maintaining breast stem cells in culture. (Pubitemid 36583168)
13. Sophos NA, Vasiliou V. Aldehyde dehydrogenase gene superfamily: The 2002 update. Chem. Biol. Interact. 143-144, 5-22 (2003). (Pubitemid 36253575)
14. Villadsen R, Fridriksdottir AJ, Ronnov-Jessen L et al. Evidence for a stem cell hierarchy in the adult human breast. J. Cell Biol. 177(1), 87-101 (2007). (Pubitemid 46588404)
15. Eirew P, Stingl J, Raouf A et al. A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability. Nat. Med. 14(12), 1384-1389 (2008).
16. Lim E, Vaillant F, Wu D et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15(8), 907-913 (2009).
17. Simoes BM, Piva M, Iriondo O et al. Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Res. Treat. DOI: 10.1007/s10549-010-1169-4 (2010) (Epub ahead of print). n First study addressing the role of estrogen in human breast stem cells.
18. Riekstina U, Cakstina I, Parfejevs V et al. Embryonic stem cell marker expression pattern in human mesenchymal stem cells derived from bone marrow, adipose tissue, heart and dermis. Stem Cell Rev. Rep. 5(4), 378-386 (2009).
19. Kristensen DM, Nielsen JE, Kalisz M et al. OCT4 and downstream factors are expressed in human somatic urogenital epithelia and in culture of epididymal spheres. Mol. Hum. Reprod. 16(11), 835-845 (2010).
20. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 414(6859), 105-111 (2001). (Pubitemid 33041634)
21. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 434(7035), 843-850 (2005). (Pubitemid 40558990)
22. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3(7), 730-737 (1997). (Pubitemid 27298715)
23. Shipitsin M, Campbell LL, Argani P et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3), 259-273 (2007). (Pubitemid 46349843)
24. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356(3), 217-226 (2007). (Pubitemid 46143225)
25. Honeth G, Bendahl PO, Ringner M et al. The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res. 10(3), R53 (2008).
26. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2(4), 333-344 (2008). (Pubitemid 351455242)
27. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl Cancer Inst. 100(9), 672-679 (2008).
28. Sheridan C, Kishimoto H, Fuchs RK et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res. 8(5), R59 (2006).
29. Abraham BK, Fritz P, Mcclellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 11(3), 1154-1159 (2005). (Pubitemid 40175765)
30. Balic M, Lin H, Young L et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12(19), 5615-5621 (2006). (Pubitemid 44629587)
31. Charafe-Jauffret E, Ginestier C, Iovino F et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16(1), 45-55 (2010).
32. Ben-Porath I, Thomson MW, Carey VJ et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40(5), 499-507 (2008). n Reveals the link between genes associated with embryonic stem cell identity and the histopathology of breast tumors. (Pubitemid 351601215)
33. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G et al. Sox2: A possible driver of the basal-like phenotype in sporadic breast cancer. Mod. Pathol. 20(4), 474-481 (2007). (Pubitemid 46482371)
34. Chen Y, Shi L, Zhang L et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J. Biol. Chem. 283(26), 17969-17978 (2008).
35. Alldridge L, Metodieva G, Greenwood C et al. Proteome profiling of breast tumors by gel electrophoresis and nanoscale electrospray ionization mass spectrometry. J. Proteome Res. 7(4), 1458-1469 (2008).
36. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10(2), R25 (2008).
37. Charafe-Jauffret E, Ginestier C, Iovino F et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69(4), 1302-1313 (2009).
38. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl Acad. Sci. USA 101(3), 781-786 (2004). (Pubitemid 38121035)
39. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 65(14), 6207-6219 (2005). (Pubitemid 40994406)
40. Engelmann K, Shen H, Finn OJ. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer Res. 68(7), 2419-2426 (2008). (Pubitemid 351521817)
41. Ponti D, Costa A, Zaffaroni N et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65(13), 5506-5511 (2005). (Pubitemid 40911148)
42. Cariati M, Naderi A, Brown JP et al. a6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int. J. Cancer 122(2), 298-304 (2008). (Pubitemid 350234715)
43. Jeter CR, Badeaux M, Choy G et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 27(5), 993-1005 (2009).
44. Vivanco M. Function follows form: Defining mammary stem cells. Sci. Transl. Med. 2(31), 31PS22 (2010).
45. Glass CK. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr. Rev. 15(3), 391-407 (1994). (Pubitemid 24180795)
46. Green S, Walter P, Kumar V et al. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A. Nature 320(6058), 134-139 (1986). (Pubitemid 16105150)
47. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl Acad. Sci. USA 93(12), 5925-5930 (1996). (Pubitemid 26190778)
48. Kuiper GG, Carlsson B, Grandien K et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and b. Endocrinology 138(3), 863-870 (1997). (Pubitemid 27089735)
49. Ricketts D, Turnbull L, Ryall G et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res. 51(7), 1817-1822 (1991).
50. Speirs V, Skliris GP, Burdall SE, Carder PJ. Distinct expression patterns of ER a and ER b in normal human mammary gland. J. Clin. Pathol. 55(5), 371-374 (2002). (Pubitemid 34494177)
51. Couse JF, Korach KS. Estrogen receptor null mice: What have we learned and where will they lead us? Endocr. Rev. 20(3), 358-417 (1999). (Pubitemid 30654784)
52. Perusinghe NP, Monaghan P, O'Hare MJ, Ashley S, Gusterson BA. Effects of growth factors on proliferation on basal and luminal cells in human breast epithelial explants in serum-free culture. In Vitro Cell Dev. Biol. 28A(2), 90-96 (1992).
53. Clarke RB, Howell A, Potten CS, Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res. 57(22), 4987-4991 (1997). (Pubitemid 27498105)
54. Russo J, Ao X, Grill C, Russo IH. Pattern of distribution of cells positive for estrogen receptor a and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat. 53(3), 217-227 (1999). (Pubitemid 29209891)
55. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010).
56. Cleator SJ, Ahamed E, Coombes RC, Palmieri C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin. Breast Cancer 9(Suppl. 1), S6-S17 (2009).
57. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001). (Pubitemid 32878711)
58. Kurian AW, Mcclure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA. Second primary breast cancer occurrence according to hormone receptor status. J. Natl Cancer Inst. 101(15), 1058-1065 (2009).
59. Shoker BS, Jarvis C, Sibson DR, Walker C, Sloane JP. Oestrogen receptor expression in the normal and pre-cancerous breast. J. Pathol. 188(3), 237-244 (1999). (Pubitemid 29317764)
60. Knight WA, Livingston RB, Gregory EJ, Mcguire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res. 37(12), 4669-4671 (1977). (Pubitemid 8239679)
61. Yang XR, Chang-Claude J, Goode EL et al. Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the Breast Cancer Association Consortium studies. J. Natl Cancer Inst. 103(3), 250-263 (2011).
62. Khan SA, Rogers MA, Obando JA, Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res. 54(4), 993-997 (1994).
63. Shoker BS, Jarvis C, Clarke RB et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am. J. Pathol. 155(6), 1811-1815 (1999).
64. Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H. Decreased expression of estrogen receptor b protein in proliferative preinvasive mammary tumors. Cancer Res. 61(6), 2537-2541 (2001). (Pubitemid 32685835)
65. Vivanco M. Biomarkers in breast cancer. Methods Mol. Biol. 593, 137-156 (2010).
66. Clemons M, Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 344(4), 276-285 (2001). (Pubitemid 32108534)
67. Planas-Silva MD, Donaher JL, Weinberg RA. Functional activity of ectopically expressed estrogen receptor is not sufficient for estrogen-mediated cyclin D1 expression. Cancer Res. 59(19), 4788-4792 (1999). (Pubitemid 29472877)
68. Jordan VC. Tamoxifen: Catalyst for the change to targeted therapy. Eur. J. Cancer 44(1), 30-38 (2008). (Pubitemid 50009873)
69. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365(9472), 1687-1717 (2005).
70. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl Cancer Inst. 97(22), 1652-1662 (2005). (Pubitemid 41672231)
71. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA, Osborne CK. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treat. 26(3), 237-246 (1993). (Pubitemid 23304239)
72. Fisher B, Costantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320(8), 479-484 (1989). (Pubitemid 19062522)
73. Rutqvist LE, Johansson H. Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer. Acta Oncol. 46(2), 133-145 (2007). (Pubitemid 46277056)
74. Liu S, Ginestier C, Charafe-Jauffret E et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc. Natl Acad. Sci. USA 105(5), 1680-1685 (2008). (Pubitemid 351346574)
75. Kok M, Koornstra RH, Margarido TC et al. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer. J. Pathol. 218(3), 316-326 (2009).
76. Lamarca HL, Rosen JM. Minireview: Hormones and mammary cell fate - what will I become when I grow up? Endocrinology 149(9), 4317-4321 (2008).
77. Mallepell S, Krust A, Chambon P, Brisken C. Paracrine signaling through the epithelial estrogen receptor a is required for proliferation and morphogenesis in the mammary gland. Proc. Natl Acad. Sci. USA 103(7), 2196-2201 (2006). (Pubitemid 43271646)
78. Ciarloni L, Mallepell S, Brisken C. Amphiregulin is an essential mediator of estrogen receptor a function in mammary gland development. Proc. Natl Acad. Sci. USA 104(13), 5455-5460 (2007). (Pubitemid 47175701)
79. Booth BW, Boulanger CA, Anderson LH, Jimenez-Rojo L, Brisken C, Smith GH. Amphiregulin mediates self-renewal in an immortal mammary epithelial cell line with stem cell characteristics. Exp. Cell Res. 316(3), 422-432 (2010).
80. Polyak K. Pregnancy and breast cancer: The other side of the coin. Cancer Cell 9(3), 151-153 (2006). (Pubitemid 43357941)
81. Medina D. Mammary developmental fate and breast cancer risk. Endocr. Relat. Cancer 12(3), 483-495 (2005). (Pubitemid 41482989)
82. Rajkumar L, Kittrell FS, Guzman RC, Brown PH, Nandi S, Medina D. Hormone-induced protection of mammary tumorigenesis in genetically engineered mouse models. Breast Cancer Res. 9(1), R12 (2007).
83. Russo J, Moral R, Balogh GA, Mailo D, Russo IH. The protective role of pregnancy in breast cancer. Breast Cancer Res. 7(3), 131-142 (2005). (Pubitemid 40704134)
84. Deroo BJ, Hewitt SC, Collins JB, Grissom SF, Hamilton KJ, Korach KS. Profile of estrogen-responsive genes in an estrogen-specific mammary gland outgrowth model. Mol. Reprod. Dev. 76(8), 733-750 (2009).
85. Fillmore CM, Gupta PB, Rudnick JA et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc. Natl Acad. Sci. USA 107(50), 21737-21742 (2010).
86. Asselin-Labat ML, Vaillant F, Sheridan JM et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465(7299), 798-802 (2010).
87. Joshi PA, Jackson HW, Beristain AG et al. Progesterone induces adult mammary stem cell expansion. Nature 465(7299), 803-807 (2010).
88. Schramek D, Leibbrandt A, Sigl V et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320), 98-102 (2010).
89. Britt KL, Kendrick H, Regan JL et al. Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells. Breast Cancer Res. 11(2), R20 (2009).
90. Siwko SK, Dong J, Lewis MT, Liu H, Hilsenbeck SG, Li Y. Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells - implications for pregnancy-induced protection against breast cancer. Stem Cells 26(12), 3205-3209 (2008).
91. Chlebowski RT, Anderson GL, Gass M et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15), 1684-1692 (2010). nn Clinical trial showing an increased risk of breast cancer in women taking estrogen and progesterone.
92. Lacroix AZ, Chlebowski RT, Manson JE et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. JAMA 305(13), 1305-1314 (2011). nn Clinical trial showing a decreased risk of breast cancer in women taking estrogen.
93. Kalmar T, Lim C, Hayward P et al. Regulated fluctuations in Nanog expression mediate cell fate decisions in embryonic stem cells. PLoS Biol. 7(7), E1000149 (2009).
94. Ellis MJ, Gao F, Dehdashti F et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A Phase 2 randomized study. JAMA 302(7), 774-780 (2009).
95. Lewis-Wambi JS, Jordan VC. Estrogen regulation of apoptosis: How can one hormone stimulate and inhibit? Breast Cancer Res. 11(3), 206 (2009).
96. Schneider J, Martin-Gutierrez S, Tresguerres JA, Garcia-Velasco JA. Circulating estradiol defines the tumor phenotype in menopausal breast cancer patients. Maturitas 64(1), 43-45 (2009).
97. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 5(4), 275-284 (2005). (Pubitemid 40488633)
98. Zhang M, Atkinson RL, Rosen JM. Selective targeting of radiation-resistant tumor-initiating cells. Proc. Natl Acad. Sci. USA 107(8), 3522-3527 (2010).
99. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361(9354), 296-300 (2003). (Pubitemid 36126189)
100. Dunn BK, Wickerham DL, Ford LG. Prevention of hormone-related cancers: Breast cancer. J. Clin. Oncol. 23(2), 357-367 (2005). (Pubitemid 46209965)
101. Vogel VG, Costantino JP, Wickerham DL et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: Preventing breast cancer. Cancer Prev. Res. (Phila.) 3(6), 696-706 (2010).
102. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 7(3), 86-95 (2005). (Pubitemid 40704127)
103. Ohno R, Asou N, Ohnishi K. Treatment of acute promyelocytic leukemia: Strategy toward further increase of cure rate. Leukemia 17(8), 1454-1463 (2003). (Pubitemid 36986946)
104. Gudas LJ, Wagner JA. Retinoids regulate stem cell differentiation. J. Cell Physiol. 226(2), 322-330 (2011).
105. Hua S, Kittler R, White KP. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137(7), 1259-1271 (2009).
106. Ginestier C, Wicinski J, Cervera N et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 8(20), 3297-3302 (2009).